Celgene Corp. on Monday said it agreed to buy Juno Therapeutics Inc. for $87 a share in cash, or about $9 billion, in a move that will expand Celgene’s portfolio of blood-cancer drugs. The Wall Street Journal reported last week the two companies were in deal talks. The deal will add a lymphoma treatment, expected to gain regulatory approval...

Source: Wall Street Journal January 22, 2018 12:22 UTC